Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 3% - What's Next?

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) shares traded down 3% during trading on Friday . The company traded as low as $24.40 and last traded at $24.65. 29,557 shares changed hands during trading, a decline of 89% from the average session volume of 257,265 shares. The stock had previously closed at $25.41.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Robert W. Baird lifted their price objective on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an "outperform" rating in a research report on Friday, November 15th. HC Wainwright reaffirmed a "buy" rating and issued a $37.00 price target on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.

Enliven Therapeutics Trading Down 4.1 %

The firm has a market cap of $1.19 billion, a price-to-earnings ratio of -12.83 and a beta of 1.08. The firm's 50-day moving average is $26.78 and its 200-day moving average is $24.13.

Insider Activity at Enliven Therapeutics

In other news, insider Joseph P. Lyssikatos sold 2,707 shares of the company's stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $27.61, for a total value of $74,740.27. Following the completion of the transaction, the insider now directly owns 1,067,180 shares in the company, valued at approximately $29,464,839.80. This represents a 0.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Benjamin Hohl sold 2,000 shares of the business's stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $25.33, for a total value of $50,660.00. The disclosure for this sale can be found here. Insiders have sold 123,945 shares of company stock valued at $3,451,099 over the last three months. 29.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Janus Henderson Group PLC boosted its stake in shares of Enliven Therapeutics by 74.8% in the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company's stock valued at $12,604,000 after purchasing an additional 305,397 shares in the last quarter. First Turn Management LLC grew its stake in shares of Enliven Therapeutics by 29.5% during the third quarter. First Turn Management LLC now owns 535,092 shares of the company's stock valued at $13,666,000 after buying an additional 121,849 shares during the last quarter. Ally Bridge Group NY LLC purchased a new position in shares of Enliven Therapeutics in the third quarter worth about $5,998,000. Bank of New York Mellon Corp increased its holdings in shares of Enliven Therapeutics by 49.2% in the second quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company's stock worth $2,667,000 after buying an additional 37,632 shares during the period. Finally, American Century Companies Inc. lifted its stake in shares of Enliven Therapeutics by 44.7% in the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company's stock valued at $646,000 after acquiring an additional 8,540 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.